Aurobindo’s shares have gained 30% so far in 2026. Investors hope the company is entering a monetization phase after years of investments. “Aurobindo, over the past five years, has invested ₹11,800 crore in its business, while it has undertaken a total capex of about ₹15,500 crore,” said Nuvama Research’s 22 June report. The company has invested across businesses such as Pen-G, injectables, biosimilars, biologics manufacturing and the Lannett acquisition.
